Incidence of venous thromboembolism after standard treatment in patients with epithelial ovarian cancer in Korea

Abstract

Background Venous thromboembolism (VTE) is a hospital‐associated severe complication that may adversely affect patient prognosis. In this study, we evaluated the incidence of VTE and its risk factors in patients with epithelial ovarian cancer (EOC). Methods We retrospectively analyzed the electronic health record data of 1268 patients with EOC who received primary treatment at the National Cancer Center, Korea between January 2007 and December 2017 to identify patients who developed VTE. Demographic, clinical, and surgical characteristics of these patients were ascertained. Competing risks analyses were performed to estimate the cumulative incidence of VTE according to the treatment type. The associations between putative risk factors and the incidence of VTE were evaluated using the Fine–Gray regression models accounting for competing risks of death. Results VTE was the most prevalent cardiovascular event, found in 9.6% (n = 122) of all patients. Of these VTE events, 115 (94.3%) occurred within 2 years of EOC diagnosis. Advanced cancer stage at diagnosis (distant vs. localized, hazards ratio [HR])= 14.49, p = 0.015) and extended hospital stay (≥15 days, HR =3.87, p = 0.004) were associated with the incidence of VTE. There was no significant difference in the cumulative incidence of VTE between primary cytoreductive surgery followed by adjuvant chemotherapy and neoadjuvant chemotherapy followed by interval cytoreductive surgery (HR =0.81, p = 0.390). Conclusions Approximately 10% of patients with EOC were diagnosed with VTE, which was the most common cardiovascular disease found in this study. The assessment of VTE risks in patients with advanced‐stage EOC with an extended hospital stay is needed to facilitate adequate prophylactic treatment.

Gynecologic Malignancy-Associated Venous Thromboembolism and Predictive Tool at Thammasat University Hospital

“…However, Ohashi et al, (2020) reported an incidence of VTE in Japanese patients with gynecologic malignancy at 5.5 (50/906) percent. The finding from the current study was in lieu with Ohashi's (5.5 %), Shin's (9.6%) and Kahr's (11%) literature, the incidence from their work might be from the inclusion of both operative and non-operative case (Ohashi et al, 2020;Shin et al, 2021, Kahr et al, 2021. In contrast, Barber et al reported from the USA in 2016 that the incidence of VTE among gynecologic malignancy operations was 1.8 percent.…”

“…Compared to the study from Japan, Korea and Denmark, the prevalence of VTE in gynecologic cancer patients varied from 5.5 to 11 percent (Ohashi et al, 2020;Shin et al, 2021, Kahr et al, 2021. In year 2021, Shin's and Kahr's groups had reported the prevalence of VTE in ovarian cancer patients among Koreans and Danes as 9.6 (122/1268) and 11(551/4991) percent (Shin et al, 2021;Kahr et al, 2021). However, Ohashi et al, (2020) reported an incidence of VTE in Japanese patients with gynecologic malignancy at 5.5 (50/906) percent.…”

Deep Learning-Based Dynamic Risk Prediction of Venous Thromboembolism for Patients With Ovarian Cancer in Real-World Settings From Electronic Health Records

“…45 Among patients with EOC, VTE is the most prevalent cardiovascular event during the initial treatment, with 85% occurring within 1 year after EOC diagnosis. 46 Other studies showed that the development of VTE within 2 years of cancer diagnosis is a significant risk factor of reduced survival, 2 and the 1-year survival rate of patients with cancer with VTE was 12%, significantly lower than 36% in the control group. 47 Our study, rooted in DL algorithms, excels in providing personalized VTE risk predictions at specific time points during the follow-up period.…”